BSX · News · 20261102N

Products and Technology

BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 31 · Surprise 42

Boston Scientific reported positive six-month primary endpoint results from the SIMPLAAFY randomized trial of its WATCHMAN FLX Pro left atrial appendage closure device. In patients with non-valvular atrial fibrillation, aspirin alone and a reduced-dose anticoagulant were each non-inferior to dual antiplatelet therapy after implantation. The results support simpler post-procedure drug regimens; the trial also reported less bleeding with the single-drug regimens and equivalent ischemic stroke rates.

Key facts

• A product liability lawsuit against Abbott joined multidistrict litigation involving similar lawsuits against Boston Scientific and Nevro concerning allegedly defective spinal cord stimulators and inadequate warnings. source
• Boston Scientific's VITALYST system is a next-generation miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. source
• Boston Scientific's VITALYST system is designed to treat acute myocardial infarction cardiogenic shock (AMI-CS). source